Ignite Creation Date:
2024-05-06 @ 12:22 AM
Last Modification Date:
2024-10-26 @ 10:49 AM
Study NCT ID:
NCT01565668
Status:
COMPLETED
Last Update Posted:
2019-12-27
First Post:
2012-03-27
Brief Title:
Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Sponsor:
Daiichi Sankyo
Organization:
Daiichi Sankyo
Study Overview
Official Title:
A Phase 2 Randomized Open-Label Study of the Safety and Efficacy of Two Doses of Quizartinib AC220 ASP2689 in Subjects With FLT3-ITD Positive Relapsed or Refractory Acute Myeloid Leukemia AML
Status:
COMPLETED
Status Verified Date:
2019-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will evaluate two doses of Quizartinib in patients with relapsed or refractory acute myeloid leukemia who are also FMS-like tyrosine kinase - internal tandem duplication FLT3-ITD positive Patient will be randomly assigned in a 11 ratio to one of two treatment arms Both treatment arms will receive Quizartinib but at different doses The study treatment is taken orally in 28 day cycles until either disease progression occurs or an unacceptable toxicity occurs In addition to the study assessments to evaluate the disease blood will be drawn to measure drug levels and biomarkers Patients will be followed for survival at three month intervals after the end of treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2011-005408-13 | EUDRACT_NUMBER | None | None |